(MAN, 55 Y/O, NON-NEOVASCULAR AMD)
A male participant, aged 55, was recruited with a diagnosis of non-neovascular AMD (age-related macular degeneration). The participant underwent a therapeutic regimen of Light Modulation® Low-Level Light Therapy (LM® LLLT) through the eye-light® solution. At baseline, the participant’s best-corrected visual acuity was ascertained to be 25 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, and Spectral-Domain Optical Coherence Tomography (SD-OCT) revealed a substantial pigment epithelial detachment (PED) accompanied by subretinal fluid at its apex.
The therapeutic protocol encompassed one session per week for a duration of four weeks, followed by one session bi-weekly for an additional two months. At a one-month follow-up subsequent to the final treatment, there was a complete reabsorption of the subretinal fluid and a collapse of the pigment epithelial detachment, with no residual retinal atrophy. The best-corrected visual acuity was recorded at 60 ETDRS letters.
FIG. 1
The picture delineates the SD-OCT images at baseline (A) which exhibit a pronounced pigment epithelial detachment (PED) with subretinal fluid. The SD-OCT image at the one-month follow-up (B) reveals a flattening
of the PED with the persistence of flat PED accompanied by hyper/hyporeflective material.
The SD-OCT image at the three-month follow-up (C) demonstrates further flattening of the PED.
FIG. 2
The exhibit portrays the baseline fundus autofluorescence (FAF) which exhibits a hyperautofluorescent ring at the periphery of the PED.
The three-month follow-up image reveals isoautofluorescence in the macular region without any legacy of retinal pigment epithelial atrophy.
FIG. 3
Illustrates the microperimetry at baseline (A) which shows a reduction in retinal sensitivity in the macular area with a mean value of 7.4 dB. The microperimetry at the three-month follow-up (B) exhibits a significant enhancement in retinal sensitivity in the macular area with a mean value of 26.5 dB.
Source
LightWave I Case Reports © 2023 Espansione Group, All Rights Reserved
About Espansione Group
Espansione Group is an established player in the medtech industry. Espansione Group strives to deliver the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group’s aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence. For more information, visit www.espansionegroup.it